[CD81 is an entry coreceptor for hepatitis C virus]
>>Published online before print May 3, 2004
Proc. Natl. Acad. Sci. USA, 10.1073/pnas.0402253101
Biochemistry
CD81 is an entry coreceptor for hepatitis C virus
Emmanuel G. Cormier *, Fay Tsamis *, Francis Kajumo *, Robert J. Durso , Jason P. Gardner , and Tatjana Dragic *
*Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461; and Progenics Pharmaceuticals, Inc., Tarrytown, NY 10591
Communicated by Samuel J. Danishefsky, Memorial Sloan-Kettering Cancer Center, New York, NY, March 30, 2004 (received for review December 9, 2003)
Hepatitis C virus (HCV) envelope glycoproteins E1/E2 can pseudotype retroviral particles and efficiently mediate entry into target cells. Using this experimental system, we determined HCV tropism for different cell types. Only primary hepatocytes and one hepatoma cell line were susceptible to HCV pseudovirus entry, which could be inhibited by sera from HCV-infected individuals. Furthermore, expression of the putative HCV receptor CD81 on nonpermissive human hepatic but not murine cells enabled HCV pseudovirus entry. Importantly, inhibition of viral entry by an anti-CD81 mAb occurred at a step following HCV attachment to target cells. Our results indicate that CD81 functions as a postattachment entry coreceptor and that other cellular factors act in concert with CD81 to mediate HCV binding and entry into hepatocytes.<<
SI interface lost some things; Kajumo, Durso, and Gardner are with Progenics. Progenics has made no announcement about this and is weak this morning. Possible trading opportunity? Not sure if this is important enough to create a move, anyhow.
Cheers, Tuck |
